• PD 0332991 (Palbociclib) HCl: Lab Guide

  2026-08-27

  A scenario-based guide to using PD 0332991 (Palbociclib) HCl, SKU A8316, in proliferation, viability, and cytotoxicity workflows. It connects CDK4/6 biology with practical handling, 3D model compatibility, dose interpretation, and evidence-based product selection.

• Biotin (Vitamin B7) for STING Assay Workflows

  2026-08-27

  Biotin (Vitamin B7) converts DNA–STING pathway questions into practical pull-down, localization, and detection assays without confusing a labeling reagent with an immune agonist. This workflow-focused guide shows how to use high-purity Biotin from APExBIO alongside biotinylated nucleic acids, labeled proteins, and streptavidin-based readouts in marine antiviral research.

• Anlotinib and VEGFR2-Driven Tumor Angiogenesis

  2026-08-26

  The reference study established anlotinib as a highly potent, orally active VEGFR2 inhibitor that suppresses angiogenesis across biochemical, cellular, ex vivo, and xenograft models. Its main contribution was linking strong target selectivity to endothelial functional responses and broader antitumor activity than sunitinib in several preclinical settings.

• Patient-Derived Gastric Cancer Assembloids Explained

  2026-08-26

  This study introduces a patient-specific gastric cancer assembloid model that combines tumor organoids with matched stromal subpopulations derived from the same tissue. The model reveals that stromal composition can reshape gene expression and drug sensitivity, supporting more physiologically relevant studies of tumor biology, resistance, and personalized treatment.

• GGFG Peptide: A Mechanistic Design Framework

  2026-08-25

  The GGFG peptide is examined as a controllable variable in bioconjugation chemistry rather than merely a passive spacer. This article connects linker architecture, assay design, analytical controls, and the mechanistic lessons of panobinostat research.

• EZ Cap™ EPO mRNA: Designing Better SCI Assays

  2026-08-25

  EZ Cap™ EPO mRNA provides a defined human erythropoietin mRNA input for studying translation, inflammation, and neurorepair. This article explains how Cap 1, ψUTP, poly(A) design, and targeted delivery controls improve assay interpretation beyond simple expression profiling.

• Acetoacetic Acid Sodium Salt: From Reagent to Readout

  2026-08-24

  Acetoacetic acid sodium salt is more than a ketone-body reagent: it is a controlled entry point for studying pH-dependent metabolism, matrix effects, and assay interpretation. This guide connects sodium 3-oxobutanoate workflows with isotope-standardization principles from translational analytical chemistry.

• X-press Tag Peptide for Mechanistic Protein Studies

  2026-08-24

  X-press Tag Peptide unifies purification, detection, and optional cleavage in an N-terminal leader peptide. This article explains how its architecture can support rigorous assays of RHEB neddylation and mTORC1 signaling without conflating workflow utility with biological causality.

• Bacitracin B1670: Protocol and QC Guide

  2026-08-23

  Bacitracin B1670 is a peptide antibiotic for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis. This guide covers solution preparation, assay controls, storage, and troubleshooting; the material is for scientific research only and should not be used for diagnostic, clinical, or medical purposes.

• Salinomycin Workflows for HCC Research

  2026-08-22

  Build more informative hepatocellular carcinoma assays with Salinomycin by pairing proliferation, apoptosis, calcium, transporter, and Wnt/β-catenin readouts. This workflow-oriented guide helps distinguish cytostatic effects from cell death while addressing ionophore-specific formulation, exposure, and toxicity considerations.

• Gemcitabine: Mechanism and Research Workflows

  2026-08-22

  Gemcitabine is a DNA synthesis inhibitor that creates replication stress and supports mechanistic cancer research. Its strongest practical use is in integrated apoptosis assay and DNA damage response assay workflows, while concentration and response remain model dependent.

• Gramine, CUL3–MTDH, and Ferroptosis in TNBC

  2026-08-21

  A 2026 study identifies gramine as a potential triple-negative breast cancer therapy that activates ferroptosis through the CUL3–MTDH ubiquitination axis. Its combination of target-engagement assays, mechanistic rescue experiments, and xenograft validation provides a useful framework for evaluating ferroptosis-inducing compounds while highlighting the need for orthogonal viability and mechanism-specific measurements.

• Cl-Amidine Workflows for PAD4 Research

  2026-08-20

  Build cleaner PAD4 inhibition experiments with practical guidance for biochemical assays, immune-cell studies, and disease-model validation. This workflow positions Cl-Amidine as a mechanistic tool while clearly separating established PAD4 applications from exploratory links to mitochondrial and lung-injury biology.

• Palbociclib: A Cell-Cycle Lens on DNA Repair

  2026-08-20

  Palbociclib (PD0332991) is more than a CDK4/6 inhibitor: it can serve as a mechanistic probe for separating cell-cycle state from DNA-repair phenotypes. This guide connects its RB-dependent activity with ERCC1- and p53-informed assay design in cancer biology research.

• Thapsigargin: From Calcium Flux to Translation

  2026-08-19

  Thapsigargin is more than a laboratory stressor: as a SERCA pump inhibitor, it provides a controllable bridge between intracellular calcium dynamics, endoplasmic reticulum stress, inflammasome signaling, and apoptosis. This thought-leadership guide shows translational researchers how to use that bridge to design stronger assays and interpret preclinical findings without overstating therapeutic relevance.

8658 records 1/578 page Next 12345 下5页 Last page